TRV734

Trevena Regains Compliance with Nasdaq Listing Requirements

Retrieved on: 
Tuesday, November 29, 2022

CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

Key Points: 
  • CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated November 28, 2022 informing Trevena that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
  • The Company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days and, as a result of regaining compliance, its common stock will continue to be listed on the Nasdaq Capital Market.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Wednesday, November 16, 2022

The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about November 18, 2022, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, is expected to be approximately $8.0 million.
  • The offering will be made only by means of a prospectus supplement that forms a part of the registration statement.

Trevena Announces Reverse Stock Split

Retrieved on: 
Wednesday, November 9, 2022

The reverse stock split is intended to enable Trevena to regain compliance with the$1.00minimum bid price required for continued listing on the Nasdaq Capital Market.The new CUSIP number for Trevenas common stock following the reverse stock split will be 89532E 208.

Key Points: 
  • The reverse stock split is intended to enable Trevena to regain compliance with the$1.00minimum bid price required for continued listing on the Nasdaq Capital Market.The new CUSIP number for Trevenas common stock following the reverse stock split will be 89532E 208.
  • The reverse stock split will affect all shares of the Companys common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Companys equity incentive plans.
  • In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the reverse stock split with a corresponding increase in exercise price per share.
  • Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing trading price per share of the common stock (as adjusted for the reverse stock split) as reported on The Nasdaq Capital Market on November 9, 2022.

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

Retrieved on: 
Wednesday, November 9, 2022

CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator. The 3-part randomized, double-blind, placebo-controlled Phase 1 study evaluated safety, tolerability and PK in healthy volunteers. TRV045 is being developed as a potential treatment for diabetic neuropathic pain (DNP). Through a collaboration with the National Institutes of Health, the Company is also exploring TRV045 as a potential treatment for epilepsy.

Key Points: 
  • Were pleased to report positive Phase 1 data on our novel S1P1 receptor modulator, TRV045, which are consistent with its distinct mechanism of action, said Carrie Bourdow, President and CEO of Trevena.
  • This study was a three-part study design, examining the PK profile, safety and tolerability of orally administered TRV045 in healthy volunteers.
  • Part 1 Single Ascending Dose: This study phase investigated the PK profile, safety and tolerability of single ascending doses of TRV045 or placebo.
  • Part 2 Food Effect: This study phase investigated the PK profile, safety and tolerability of TRV045 administered with a high-fat meal in 3 study cohorts.

Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022

Retrieved on: 
Monday, November 7, 2022

The conference call will be webcast live from the Companys website and will be available via the following links:

Key Points: 
  • The conference call will be webcast live from the Companys website and will be available via the following links:
    The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Companys website.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Wednesday, September 7, 2022

CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York.

Key Points: 
  • CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York.
  • A replay of the presentation will be archived on the website and available for approximately 30 days following the event.
  • Please contact your H.C. Wainwright representative to schedule one-on-one meetings with Trevena during the conference.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022

Retrieved on: 
Monday, August 8, 2022

The conference call will be webcast live from the Companys website and will be available via the following links:

Key Points: 
  • The conference call will be webcast live from the Companys website and will be available via the following links:
    The webcast should be accessed 15 minutes prior to the conference call start time.
  • A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Companys website.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock

Retrieved on: 
Friday, July 29, 2022

Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.

Key Points: 
  • Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.
  • The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock.
  • The shares of preferred stock are convertible at the option of the holder at any time following the date of issuance.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is $2 million.

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock

Retrieved on: 
Friday, July 29, 2022

Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.

Key Points: 
  • Each share of preferred stock has a stated value of $1,000 per share and a conversion price of $0.25 per share.
  • The shares of preferred stock issued in the offering are convertible into an aggregate of 8,000,000 shares of common stock.
  • The shares of preferred stock are convertible at the option of the holder at any time following the date of issuance.
  • Total gross proceeds from the offering, before deducting the placement agent's fees and other estimated offering expenses, is $2 million.

Trevena to Participate at the JMP Securities Life Sciences Conference

Retrieved on: 
Friday, June 10, 2022

A replay of the presentation will be archived on the website and available for approximately 30 days following the event.

Key Points: 
  • A replay of the presentation will be archived on the website and available for approximately 30 days following the event.
  • Please contact your JMP Securities representative to schedule virtual one-on-one meetings with Trevena during the conference.
  • Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders.
  • In addition, the forward-looking statements included in this press release represent the Companys views only as of the date hereof.